These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17284993)

  • 1. Renal protective strategies in heart transplant patients.
    Cantarovich M
    Curr Opin Cardiol; 2007 Mar; 22(2):133-8. PubMed ID: 17284993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible role of everolimus in improving renal function in long-term heart transplantation.
    Fiocchi R; Iacovoni A; Sebastiani R; Fontana A; Gandolfi L; Gamba A
    Transplant Proc; 2007; 39(6):1967-9. PubMed ID: 17692667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of renal dysfunction in the liver transplant recipient.
    Pham PT; Pham PC; Wilkinson AH
    Curr Opin Organ Transplant; 2009 Jun; 14(3):231-9. PubMed ID: 19395967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of some selected risk factors in the development of the nephrotoxicity of immunosuppressive medications used after the heart transplantation in children and young adults].
    Hyla-Klekot L; Kucharska G
    Przegl Lek; 2006; 63 Suppl 3():40-3. PubMed ID: 16898485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimization of immunosuppression in kidney transplantation.
    Augustine JJ; Hricik DE
    Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):535-41. PubMed ID: 18089967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for immunosuppression in lung transplantation.
    Hopkins PM; McNeil K
    Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL; Taber DJ
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H
    J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic renal dysfunction following liver transplantation.
    Schmitz V; Laudi S; Moeckel F; Puhl G; Stockmann M; Tran ZV; Kahl A; Neumann U; Neuhaus P
    Clin Transplant; 2008; 22(3):333-40. PubMed ID: 18341597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bergamo Kidney Transplant Program.
    Perico N; Cravedi P; Ruggenenti P; Gotti E; Rota G; Locatelli G; Gambara V; Perna A; Rota S; Remuzzi G
    Clin Transpl; 2005; ():85-100. PubMed ID: 17424727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I; Hsaiky L; Brown K; Abouljoud M
    Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.